安進(jìn)(Amgen)和施維雅(Servier)8月12日宣布,提前結(jié)束了與此2013年7月8日達(dá)成的心血管產(chǎn)品合作有關(guān)的《哈特—斯科特—羅迪諾反托拉斯改進(jìn)法》(HSR法案)等待期,完成了該筆交易。
根據(jù)協(xié)議條款,安進(jìn)獲得施維雅開(kāi)發(fā)的新型口服藥物在美國(guó)的商業(yè)化權(quán)利,該藥已以品牌名Procoralan獲歐盟批準(zhǔn),用于慢性心臟衰竭和穩(wěn)定型心絞痛患者心率升高的治療。安進(jìn)同時(shí)獲得了施維雅實(shí)驗(yàn)性分子S38844用于心血管疾病的美國(guó)獨(dú)家開(kāi)發(fā)和商業(yè)化權(quán)利。目前,S38844處于II期臨床開(kāi)發(fā),用于心臟衰竭的治療。
通過(guò)合作,施維雅獲得安進(jìn)omecamtiv mecarbil在歐盟的獨(dú)家商業(yè)化權(quán)利。omecamtiv mecarbil是一種心肌肌球蛋白(myosin)的激活劑,目前正測(cè)試用于收縮功能障礙(systolic dysfunction)患者心臟衰竭的治療潛力。
英文原文:Amgen, Inc. : Amgen And Servier Complete Product Collaboration Transaction
08/12/2013 | 06:15pm US/EasternRecommend: 0
THOUSAND OAKS, Calif. and SURESNES, France, Aug. 12, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Servier today announced the early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in connection with the cardiovascular product collaboration agreement announced on July 8, 2013, completing the transaction.
Under the terms of the agreement, Amgen has obtained commercial rights in the U.S. to Servier's novel oral drug, approved in the EU as Procoralan(?) (ivabradine), for chronic heart failure and stable angina in patients with elevated heart rates. Amgen has also received an exclusive option to develop and commercialize Servier's investigational molecule, S38844, for cardiovascular diseases in the U.S. Currently, S38844 is in Phase 2 studies for the treatment of heart failure. Through the collaboration, Servier has obtained an exclusive option to commercialize omecamtiv mecarbil in Europe. Omecamtiv mecarbil is an activator of cardiac myosin, which is currently being tested for potential applications in the treatment of heart failure in patients with systolic dysfunction. |